Comparing hospital prices to drug prices is absurd. And although the article claims to be about prices, the chart actually shows National Health Expenditure (NHE) spending numbers, not prices.

Despite that, hospital spending has grown at a slower rate than drug spending over the time period displayed in the chart. And as a percentage of the NHE, hospital care actually declined from 42.7 percent in 1980 to 34 percent in 2016, compared to retail prescription drug spending, which doubled as a share of total national health expenditures. The NHE data don’t separate drugs used together in a hospital setting out from overall hospital spending, so there is drug spending hidden within the hospital numbers.

As global pharmaceutical giants pocket record profits, one out of every four American hospitals operates in the red. But the gravity of the health care cost problem requires all stakeholders, especially pharmaceutical companies,  to work towards a solution that helps reduce costs for patients.

That's why hospitals and health systems are redesigning their delivery systems and embracing new reimbursement models. They're leveraging technology to treat patients at home and offer specialized care to underserved communities.

Hospital prices have also grown more slowly than drug prices, despite rising input costs. Hospital price growth as measured by the Producer Price Index, has remained under 2 percent for each of the last four years. Even before that, since 2008, hospital prices had an average annual growth rate of 2 percent.

In comparison, the overall price of medical care had an average annual growth rate of 3 percent, while drug prices had a significantly higher average annual growth rate of 5.6 percent for that same time period.

Headline
The AHA commented today on the Centers for Medicare & Medicaid Services’ proposed rule on the Global Benchmark for Efficient Drug Pricing Model, or…
Headline
The Administration for Strategic Preparedness and Response Feb. 18 announced an investment that will focus on resolving a frequent shortage of oseltamivir,…
Headline
The House Energy and Commerce Subcommittee on Health Feb. 11 hosted a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the…
Headline
The White House yesterday launched TrumpRx, the direct-to-consumer platform that will serve as a hub to direct cash-paying consumers to drug manufacturers…
Headline
The Department of Labor has issued a proposed rule to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to disclose…
Headline
The Department of Health and Human Services Office of Inspector General Jan. 27 released a bulletin addressing how direct-to-consumer drug programs can sell…